Ultragenyx Pharmaceutical (RARE) Share-based Compensation (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Share-based Compensation data on file, last reported at $30000.0 in Q1 2026.

• Quarterly Share-based Compensation fell 25.0% year-over-year to $30000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $113.1 million (down 6.59% YoY) and the FY2025 annual result came in at $153.0 million, down 3.16% from the prior year.
• Share-based Compensation retreated to $30000.0 in Q1 2026 per RARE's latest filing, from $37.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $41.6 million in Q3 2024 and bottomed at $30000.0 in Q1 2026.
• The 5-year median for Share-based Compensation is $35.8 million (2022), against an average of $31.6 million.
• The widest annual swing landed in 2022, when Share-based Compensation soared 32.5%; it then slumped 99.89% in 2025.
• Tracing RARE's Share-based Compensation over 5 years: stood at $29.4 million in 2022, then climbed by 14.18% to $33.5 million in 2023, then advanced by 19.74% to $40.1 million in 2024, then fell by 6.65% to $37.5 million in 2025, then slumped by 99.92% to $30000.0 in 2026.
• Per Business Quant, the three latest RARE Share-based Compensation figures stand at $30000.0 (Q1 2026), $37.5 million (Q4 2025), and $37.0 million (Q3 2025).

Peer Comparison